KRAS mutation: from undruggable to druggable in cancer
Open accessThe DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.
Abstract
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of KRAS is constantly being updated by numerous studies on KRAS in the initiation and progression of cancer diseases. However, KRAS has been deemed a challenging therapeutic target, even “undruggable”, after drug-targeting efforts over the past four decades. Recently, there have been surprising advances in directly targeted drugs for KRAS, especially in KRAS (G12C) inhibitors, such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have obtained encouraging results in clinical trials. Excitingly, AMG510 was the first drug-targeting KRAS (G12C) to be approved for clinical use this year. This review summarises the most recent understanding of fundamental aspects of KRAS, the relationship between the KRAS mutations and tumour immune evasion, and new progress in targeting KRAS, particularly KRAS (G12C). Moreover, the possible mechanisms of resistance to KRAS (G12C) inhibitors and possible combination therapies are summarised, with a view to providing the best regimen for individualised treatment with KRAS (G12C) inhibitors and achieving truly precise treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS is the most frequently mutated oncogene, accounting for approximately 85% of all RAS mutations in 20–25% of all cancers [8–10].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the various KRAS mutations in human cancers, G12C, G12D, G12V, and G12A are the most prevalent (2).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“KRAS mutations most commonly occur at the 12th codon near the nucleotide-binding site, with less prevalent mutations occurring at codons 13, 61, and 146 within other catalytic domains (Figure 1b,c) [23].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogene in various types of human cancers such as pancreatic, lung, and colorectal cancer, with G12, G13, and Q61 being the most prevalent mutant codons observed (1, 2).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, potent inhibition through covalent modification has enabled targeting of traditionally ‘undruggable’ proteins, exemplified by the approval of sotorasib (Amgen), which is an inhibitor of mutant KRAS(G12C), a GTPase that resisted decades of drug discovery efforts9,10”
From Advances in covalent drug discovery (2022) · cites this paper as [10]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–238 of 238
A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
Granville, C. A., Memmott, R. M., Balogh, A., Mariotti, J., Kawabata, S., Han, W., LoPiccolo, J., Foley, J., Liewehr, D. J., Steinberg, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005061 · Cited by 80
Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80
Mak, R. H., Hermann, G., Lewis, J. H., Aerts, H. J. W. L., Baldini, E. H., Chen, A. B., Colson, Y. L., Hacker, F., Kozono, D., Wee, J. O., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.005 · Cited by 79
Bange, E., Marmarelis, M. E., Hwang, W.-T., Yang, Y.-X., Thompson, J. C., Rosenbaum, J., Bauml, J. M., Ciunci, C., Alley, E. W., Cohen, R. B., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00326 · Cited by 74
EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation
Wang, M., Kern, A. M., Hülskötter, M., Greninger, P., Singh, A., Pan, Y., Chowdhury, D., Krause, M., Baumann, M. A., Benes, C. H., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3157 · Cited by 73
Plowman, S. J., Berry, R. L., Bader, S. A., Luo, F., Arends, M. J., Harrison, D. J., Hooper, M. L., & Patek, C. E. (2006) · PubMed · Cited by 69
Affinity of guanine nucleotide binding proteins for their ligands: facts and artefacts
Goody, R. S., Frech, M., & Wittinghofer, A. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90134-h · Cited by 68
Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down
Hobbs, G. A., Wittinghofer, A., & Der, C. J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.015 · Cited by 68
CXCR2 signaling promotes secretory cancer‐associated fibroblasts in pancreatic ductal adenocarcinoma
Awaji, M., Saxena, S., Wu, L., Prajapati, D. R., Purohit, A., Varney, M. L., Kumar, S., Rachagani, S., Ly, Q. P., Jain, M., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902990r · Cited by 68
Petanidis, S., Anestakis, D., Argyraki, M., Hadzopoulou-Cladaras, M., & Salifoglou, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073616 · Cited by 67
Saqcena, M., Mukhopadhyay, S., Hosny, C., Alhamed, A., Chatterjee, A., & Foster, D. A. (2015) · Oncogene · doi:10.1038/onc.2014.207 · Cited by 67
Cytoplasmic protein granules organize kinase-mediated RAS signalingPreprint
Tulpule, A., Guan, J., Neel, D. S., Lin, Y., Heslin, A., Allegakoen, H. R., Perati, S., Ramirez, A. D., Shi, X.-Y., Yang, B., et al. (2019) · bioRxiv · doi:10.1101/704312 · Cited by 63
Jia, Y., Jiang, T., Li, X., Zhao, C., Zhang, L., Zhao, S., Liu, X., Qiao, M., Luo, J., Shi, J., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7016 · Cited by 60
A new mechanism for the regulation of Gab1 recruitment to the plasma membrane
Eulenfeld, R., & Schaper, F. (2009) · Journal of Cell Science · doi:10.1242/jcs.037226 · Cited by 57
Gurtner, K., Kryzmien, Z., Koi, L., Wang, M., Benes, C. H., Hering, S., Willers, H., Baumann, M. A., & Krause, M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32598 · Cited by 54
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Loong, H. H.-F., Du, N., Cheng, C., Lin, H., Guo, J., Lin, G., Li, M., Jiang, T., Shi, Z., Cui, Y., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-455 · Cited by 54
Smakman, N., Veenendaal, L. M., van Diest, P. J., Bos, R., Offringa, R., Rinkes, I. H. M. B., & Kranenburg, O. (2005) · Oncogene · doi:10.1038/sj.onc.1208995 · Cited by 51
Drugan, J. K., Rogers-Graham, K., Gilmer, T., Campbell, S., & Clark, G. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004386200 · Cited by 50
FDA Approves First KRAS Inhibitor: Sotorasib
(2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2021-0362 · Cited by 47
Kelly, M. R., Kostyrko, K., Han, K., Mooney, N. A., Jeng, E. E., Spees, K., Dinh, P. T., Abbott, K. L., Gwinn, D. M., Sweet-Cordero, E. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1274 · Cited by 44
SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF β-receptor
Ekman, S., Kallin, A., Engström, U., Heldin, C., & Rönnstrand, L. (2002) · Oncogene · doi:10.1038/sj.onc.1205210 · Cited by 43
Liu, W., Yin, Y., Wang, J., Shi, B., Zhang, L., Qian, D., Li, C., Zhang, H., Wang, S., Zhu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10162 · Cited by 42
Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
Yaeger, R., & Solit, D. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4060 · Cited by 39
Srikar, R., Suresh, D., Zambre, A., Taylor, K., Chapman, S., Leevy, M., Upendran, A., & Kannan, R. (2016) · Scientific Reports · doi:10.1038/srep30245 · Cited by 38
Properties of a Murine Sarcoma Virus1
KIRSTEN, W. H., Schauf, V., & McCoy, J. L. (2015) · Proceedings of the International Symposium on Comparative Leukemia Research · doi:10.1159/000391714 · Cited by 37
Papadopoulos, K. P., Ou, S.-H. I., Johnson, M. L., Christensen, J., Velastegui, K., Potvin, D., Faltaos, D., & Chao, R. C. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps3161 · Cited by 37
Zheng, S., Wang, X., Fu, Y., Li, B., Xu, J., Wang, H., Huang, Z. K., Xu, H., Qiu, Y., Shi, Y.-Z., et al. (2021) · Bioengineered · doi:10.1080/21655979.2021.1890382 · Cited by 37
Majmudar, J. D., Hodges, H. B., Hahne, K., Donelson, J. L., Song, J., Shrestha, L., Harrison, M. L., Hrycyna, C. A., & Gibbs, R. A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.087 · Cited by 35
Mutant Ras Elevates Dependence on Serum Lipids and Creates a Synthetic Lethality for Rapamycin
Salloum, D., Mukhopadhyay, S., Tung, K. H.-Y., Polonetskaya, A., & Foster, D. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0762 · Cited by 33
KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients
Gao, W., Jin, J., Yin, J., Land, S. R., Gaither‐Davis, A., Christie, N. A., Luketich, J. D., Siegfried, J. M., & Keohavong, P. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22501 · Cited by 32
Mutant KRAS at the heart of tumor immune evasion
van Maldegem, F., & Downward, J. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.013 · Cited by 32
Liu, R., Zhang, Y., Smolen, P. D., Cleary, L. J., & Byrne, J. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-57484-y · Cited by 26
Targeting cytokine networks in KRAS-driven tumorigenesis
Golay, H. G., & Barbie, D. A. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.928596 · Cited by 22
Testorelli, C., Bussini, S., Filippi, R. D., Marelli, O., Orlando, L., Greiner, J. W., Grohmann, U., Tentori, L., Giuliani, A., Bonmassar, E., et al. (1997) · PubMed · Cited by 20
ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
Bogucka, K., Marini, F., Rosigkeit, S., Schlöder, J., Jonuleit, H., David, K. A., Schlackow, M., & Rajalingam, K. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00245-w · Cited by 14
Another KRAS Inhibitor Holds Its Own
(2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2020-098 · Cited by 12
Kelly, M. R., Kostyrko, K., Han, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.20.051623 · Cited by 9
Putting the brakes on KRAS-G12C nucleotide cycling
Shipman, L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.13 · Cited by 4
Research works printed but not linked: 6
- Hunter JC Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations Mol. Cancer Res. 2015 13 1325 1335 26037647 · DOI · Paper page
- Hunter JC Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations Mol. Cancer Res 2015 13 1325 1335 26037647 · DOI · Paper page
- Romero R Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis Nat. Med 2017 23 1362 1368 28967920 PMC5677540 · DOI · Paper page
- Hallin J The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Cancer Disco. 2020 10 54 71 PMC6954325 31658955 · DOI · Paper page
- Hallin J The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Cancer Discov. 2020 10 54 71 31658955 PMC6954325 · DOI · Paper page
- Tanaka N Clinical Acquired Resistance to KRAS Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation Cancer Discov. 2021 11 1913 1922 33824136 PMC8338755 · DOI · Paper page
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
“Cycling between these two forms is regulated by GTPase-activating proteins, guanine nucleotide exchange factors and guanine nucleotide dissociation inhibitors 87 .”
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Endometriosis and adenomyosis: shared pathophysiology
Bulun, S. E., Yildiz, S., Adli, M., Chakravarti, D., Parker, J. B., Milad, M., Yang, L., Chaudhari, A., Tsai, S., Wei, J. J., et al. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.03.006 · Cited by 216
Expanding PROTACtable genome universe of E3 ligases
Liu, Y., Yang, J., Wang, T., Luo, M., Chen, Y., Chen, C., Ronai, Z., Zhou, Y., Ruppin, E., & Han, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42233-2 · Cited by 186
Metadata
- Authors
- Huang, L., Guo, Z., Wang, F., & Fu, L.
- Affiliations
- Sun Yat-sen University (CN)
- Corresponding author
- Fu, Liwu
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-11-15
- Volume
- 6
- Issue
- 1
- Pages
- 386-386
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8591115
- OpenAlex
- W3214173072
- Cited by
- 1,127
- References
- 240
- Citations by year
- 2026: 251 · 2025: 346 · 2024: 289 · 2023: 178 · 2022: 62
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82073882)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS mutation, KRAS G12C inhibitors, sotorasib, adagrasib, targeted cancer therapy, tumor immune evasion, drug resistance mechanisms, combination therapy, oncogenes, precision oncology
- MeSH terms
- Humans, Neoplasms, Proto-Oncogene Proteins p21(ras), Amino Acid Substitution, Mutation, Missense, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.